Catawba Capital Management Va adds Meridian Bioscience (VIVO) to its portfolio

Meridian Bioscience (VIVO) : Catawba Capital Management Va added new position in Meridian Bioscience during the most recent quarter end. The investment management firm now holds 15,065 shares of Meridian Bioscience which is valued at $288,344 , the company said in a statement filed on Oct 7, 2016 with the SEC.Meridian Bioscience makes up approximately 0.07% of Catawba Capital Management Va’s portfolio.

Other Hedge Funds, Including , Randolph Co Inc boosted its stake in VIVO in the latest quarter, The investment management firm added 3,200 additional shares and now holds a total of 110,400 shares of Meridian Bioscience which is valued at $2,113,056. Meridian Bioscience makes up approx 0.54% of Randolph Co Inc’s portfolio.Bnp Paribas Arbitrage Sa reduced its stake in VIVO by selling 6,686 shares or 47.51% in the most recent quarter. The Hedge Fund company now holds 7,387 shares of VIVO which is valued at $140,796.Eqis Capital Management boosted its stake in VIVO in the latest quarter, The investment management firm added 2,791 additional shares and now holds a total of 34,131 shares of Meridian Bioscience which is valued at $650,537. Meridian Bioscience makes up approx 0.04% of Eqis Capital Management’s portfolio.

Meridian Bioscience opened for trading at $19.14 and hit $19.22 on the upside on Friday, eventually ending the session at $19.14, with a gain of 0.37% or 0.07 points. The heightened volatility saw the trading volume jump to 1,11,369 shares. Company has a market cap of $806 M.

On the company’s financial health, Meridian Bioscience reported $0.21 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus of $0.22. The company had revenue of $50.70 million for the quarter, compared to analysts expectations of $52.87 million. The company’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.22 EPS.

Meridian Bioscience Inc. (Meridian) is an integrated life science company. The Company is engaged in developing manufacturing selling and distribution of clinical diagnostic test kits for certain gastrointestinal viral respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens antibodies polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents nucleotides competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company operates in two segments: Diagnostics and Life Science.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Meridian Bioscience - Is it time to Sell?

Top Brokerage Firms are advising their investors on Meridian Bioscience. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.